Kronos Bio Inc. (KRON)
Kronos Bio Statistics
Share Statistics
Kronos Bio has 60.97M shares outstanding. The number of shares has increased by 1.46% in one year.
| Shares Outstanding | 60.97M |
| Shares Change (YoY) | 1.46% |
| Shares Change (QoQ) | 1.04% |
| Owned by Institutions (%) | 32.58% |
| Shares Floating | 39.23M |
| Failed to Deliver (FTD) Shares | 4 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 527.68K, so 0.87% of the outstanding shares have been sold short.
| Short Interest | 527.68K |
| Short % of Shares Out | 0.87% |
| Short % of Float | 1.36% |
| Short Ratio (days to cover) | 8.81 |
Valuation Ratios
The PE ratio is -0.66 and the forward PE ratio is -0.74. Kronos Bio's PEG ratio is 0.02.
| PE Ratio | -0.66 |
| Forward PE | -0.74 |
| PS Ratio | 5.79 |
| Forward PS | 1 |
| PB Ratio | 0.65 |
| P/FCF Ratio | -0.87 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Kronos Bio.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.54, with a Debt / Equity ratio of 0.28.
| Current Ratio | 7.54 |
| Quick Ratio | 7.54 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | -0.4 |
| Debt / FCF | -0.38 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $984.8K |
| Profits Per Employee | $-8.61M |
| Employee Count | 10 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -31.25% in the last 52 weeks. The beta is 1.79, so Kronos Bio's price volatility has been higher than the market average.
| Beta | 1.79 |
| 52-Week Price Change | -31.25% |
| 50-Day Moving Average | 0.93 |
| 200-Day Moving Average | 1 |
| Relative Strength Index (RSI) | 31.47 |
| Average Volume (20 Days) | 187.43K |
Income Statement
In the last 12 months, Kronos Bio had revenue of 9.85M and earned -86.08M in profits. Earnings per share was -1.43.
| Revenue | 9.85M |
| Gross Profit | 9.85M |
| Operating Income | -92.89M |
| Net Income | -86.08M |
| EBITDA | -61.72M |
| EBIT | -63.43M |
| Earnings Per Share (EPS) | -1.43 |
Balance Sheet
The company has 84.57M in cash and 24.9M in debt, giving a net cash position of 59.67M.
| Cash & Cash Equivalents | 84.57M |
| Total Debt | 24.9M |
| Net Cash | 59.67M |
| Retained Earnings | -594.94M |
| Total Assets | 124.36M |
| Working Capital | 99.95M |
Cash Flow
In the last 12 months, operating cash flow was -65.44M and capital expenditures -4K, giving a free cash flow of -65.44M.
| Operating Cash Flow | -65.44M |
| Capital Expenditures | -4K |
| Free Cash Flow | -65.44M |
| FCF Per Share | -1.09 |
Margins
Gross margin is 100%, with operating and profit margins of -943.21% and -874.08%.
| Gross Margin | 100% |
| Operating Margin | -943.21% |
| Pretax Margin | -874.08% |
| Profit Margin | -874.08% |
| EBITDA Margin | -626.69% |
| EBIT Margin | -943.21% |
| FCF Margin | -664.49% |
Dividends & Yields
KRON does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for KRON is $1.62, which is 110.4% higher than the current price. The consensus rating is "Hold".
| Price Target | $1.62 |
| Price Target Difference | 110.4% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -6.61 |
| Piotroski F-Score | 4 |